课题基金 / 基金详情

ESI-TOF Mass Spectrometer for Molecular Mass Analysis: Proteins/Small Molecules

ESI-TOF Mass Spectrometer for Molecular Mass Analysis: Proteins/Small Molecules
用于分子质量分析的 ESI-TOF 质谱仪:蛋白质/小分子
批准号:
8447919
负责人:
SUSAN T WEINTRAUB
金额:
$16.53万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-07-19 至 2014-07-18

项目摘要

项目成果

SUSAN T WEINTRAUB的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):申请资金用于购买Agilent 6224 ESI-TOF质谱仪,用于在圣安东尼奥德克萨斯大学健康科学中心(UTHSCSA)的研究人员进行蛋白质,肽和“小”分子的分子质量测定。所要求的仪器将增加有价值的新功能,以补充现有的质谱实验室(MSL),该实验室多年来提供了广泛的蛋白质组学服务。发起获得ESI-TOF质谱仪的努力的动力来自于在UTHSCSA生物化学系建立了一个蛋白质生产设施,该设施的建立是为了帮助那些需要相对大量的纯化蛋白质用于结构/生物物理研究,但在自己的实验室没有能力产生所需蛋白质的研究人员。ESI-TOF/MS仪器在市场上的初步探索发生在2010年中期。由于当时没有足够的资金购买仪器,安捷伦的代表向PI提出了对ESI-TOF/MS进行现场评估的可能性。安捷伦6224于2011年夏季安装在MSL中,并在几个月后集成到实验室工作流程中。该仪器已迅速成为支持许多研究项目的必要工具,特别是美国国立卫生研究院资助的一项研究,重点是发现新的天然产物和合成化合物,以提供更有效的癌症治疗方法。使用Agilent 6224分析蛋白质样品的研究人员现在认识到,与1-D SDS PAGE和Western blotting提供的远不精确的评估相比,获得有关蛋白质的准确和更全面的分子质量信息具有实质性的好处。如果这项建议得到资助,该仪器将在一个开放获取的环境中提供,这样,经过适当的培训,用户实验室的工作人员/学生将能够在MSL人员的少量监督下进行自己的分析。所要求的ESI-TOF质谱仪的分析将比目前通过MSL提供的更准确,更具成本效益和更快的周转时间,并且将适用于更广泛的溶液组成样品。与安捷伦的协议是为期一年的评估,尽管希望时间可以延长,直到该提案的审查结束
英文摘要
DESCRIPTION (provided by applicant): Funds are requested to purchase an Agilent 6224 ESI-TOF mass spectrometer for molecular mass determination of proteins, peptides and "small" molecules for investigators at the University of Texas Health Science Center at San Antonio (UTHSCSA). The requested instrument will add valuable new capabilities to complement the existing Mass Spectrometry Laboratory (MSL) that has offered a wide range of proteomics services for many years. The impetus for initiating the effort to obtain an ESI-TOF mass spectrometer came from the establishment of a protein production facility in the UTHSCSA Department of Biochemistry that was set up to help investigators who require relatively large quantities of purified proteins for structural/biophysical studies but do not have the capacity in their own laboratory to generate the requisite protein. Initial exploration of ESI-TOF/MS instruments on the market took place in mid 2010. Because sufficient funds were not available at that time to purchase an instrument, representatives from Agilent approached the PI about the possibility of an on-site evaluation of an ESI-TOF/MS. An Agilent 6224 was installed in the MSL in summer 2011 and was integrated into the laboratory workflow several months later. The instrument has quickly become essential for support of many research projects, in particular, an NIH-funded investigation focusing on discovery of new natural products and synthetic compounds to provide more effective therapies for the treatment of cancer. Investigators who have had protein samples analyzed on the Agilent 6224 now recognize the substantial benefit of obtaining accurate and more comprehensive molecular mass information about their proteins as compared to the far less precise assessment provided by 1-D SDS PAGE and Western blotting. If this proposal is funded, the instrument will be made available in an open-access environment such that after proper training, staff/students from the users' laboratories will be able to conduc their own analyses with only minor supervision from MSL personnel. Analyses on the requested ESI-TOF mass spectrometer will be much more accurate, more cost-effective and with a faster turn-around time than is currently available through the MSL, and will be amenable to samples in a wider range of solution compositions. The agreement with Agilent is for a one-year evaluation, although it is hoped that the time can be extended until the review of this proposal is completed. The acquisition of an ESI-TOF mass spectrometer for molecular mass determination has the potential to positively impact a large number of NIH-funded investigations covering the full array of disciplines in biomedical research.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Orbitrap Exploris 480 Mass Spectrometer for Biomedical Research
Triple Quadrupole Mass Spectrometer for Metabolomics Analysis
MASS SPECTROMETRY SHARED RESOURCE
Orbitrap XL/ETD Mass Spectrometer
海外基金